Clinical outcome of various regimens of gonadotropin-releasing hormone analogues after conservative surgery in patients with endometriosis

Wei Liu, Chao Chen, Jun Shi, Xingxing Zang, Ai Min Zhao

Research output: Contribution to journalArticle

Abstract

Objective: To assess the efficacy of three GnRHa therapies after conservative surgery for ovarian endometriosis by analyzing sex hormones, hypo-estrogenic symptoms, quality of life and bone mineral density. Methods: Thirty-six ovarian endometriosis patients with 20 to 48 years old were divided into three groups after conservative surgery according to their own wills. GnRHa conventional dosage regimen group was intramuscularly injected of triptorelin 3.75 mg every 4 weeks. Tibolone ‘add-back’ therapy group received the same treatment as the conventional group and orally took tibolone tablets 1.25 mg/d from the eighth week. GnRHa extended-interval dosage group received a 4-dose regimen every 6 weeks. The treatment lasted for 24 weeks. The EMs (VAS score), menopausal score, recurrence, menstruation and vaginal bleeding were assessed. The levels in sex hormones, bone metabolism indicators, lumbar spine bone mineral density, CA125 and other parameters were observed. Results: The symptoms including dysmenorrhea, dyspareunia and chronic pelvic pain were relieved in three groups. At 12th and 24th week of GnRHa treatment, the levels of serum sex hormones (FSH, LH and E2) in all groups were decreased compared with the baseline, the modified Kupperman scores in Tibolone ‘add-back’ group and extended-interval group were lower than those of the conventional group. At the end of the 24th week, T scores and CA125 serum in all groups were decreased compared with the baseline. Conclusions: Tibolone ‘add-back’ therapy and GnRHa extended-interval regimen had better effects on improving symptoms of perimenopause than GnRHa conventional regimens. Tibolone ‘add-back’ therapy was more effective in protection of bone density than other treatments.

Original languageEnglish (US)
Article numberIJCEM0027833
Pages (from-to)19935-19943
Number of pages9
JournalInternational Journal of Clinical and Experimental Medicine
Volume9
Issue number10
StatePublished - Oct 30 2016

Fingerprint

tibolone
Endometriosis
Gonadotropin-Releasing Hormone
Surgery
Bone
Gonadal Steroid Hormones
Bone Density
Minerals
Triptorelin Pamoate
Therapeutics
Perimenopause
Dyspareunia
Dysmenorrhea
Pelvic Pain
Menstruation
Uterine Hemorrhage
Metabolism
Tablets
Group Psychotherapy
Serum

Keywords

  • Conservative surgery
  • Endometriosis
  • Gonadotropin-releasing hormone analogues
  • Tibolone
  • ‘Add-back’ therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Clinical outcome of various regimens of gonadotropin-releasing hormone analogues after conservative surgery in patients with endometriosis. / Liu, Wei; Chen, Chao; Shi, Jun; Zang, Xingxing; Zhao, Ai Min.

In: International Journal of Clinical and Experimental Medicine, Vol. 9, No. 10, IJCEM0027833, 30.10.2016, p. 19935-19943.

Research output: Contribution to journalArticle

@article{922f0fb090e44540ba016132f8570363,
title = "Clinical outcome of various regimens of gonadotropin-releasing hormone analogues after conservative surgery in patients with endometriosis",
abstract = "Objective: To assess the efficacy of three GnRHa therapies after conservative surgery for ovarian endometriosis by analyzing sex hormones, hypo-estrogenic symptoms, quality of life and bone mineral density. Methods: Thirty-six ovarian endometriosis patients with 20 to 48 years old were divided into three groups after conservative surgery according to their own wills. GnRHa conventional dosage regimen group was intramuscularly injected of triptorelin 3.75 mg every 4 weeks. Tibolone ‘add-back’ therapy group received the same treatment as the conventional group and orally took tibolone tablets 1.25 mg/d from the eighth week. GnRHa extended-interval dosage group received a 4-dose regimen every 6 weeks. The treatment lasted for 24 weeks. The EMs (VAS score), menopausal score, recurrence, menstruation and vaginal bleeding were assessed. The levels in sex hormones, bone metabolism indicators, lumbar spine bone mineral density, CA125 and other parameters were observed. Results: The symptoms including dysmenorrhea, dyspareunia and chronic pelvic pain were relieved in three groups. At 12th and 24th week of GnRHa treatment, the levels of serum sex hormones (FSH, LH and E2) in all groups were decreased compared with the baseline, the modified Kupperman scores in Tibolone ‘add-back’ group and extended-interval group were lower than those of the conventional group. At the end of the 24th week, T scores and CA125 serum in all groups were decreased compared with the baseline. Conclusions: Tibolone ‘add-back’ therapy and GnRHa extended-interval regimen had better effects on improving symptoms of perimenopause than GnRHa conventional regimens. Tibolone ‘add-back’ therapy was more effective in protection of bone density than other treatments.",
keywords = "Conservative surgery, Endometriosis, Gonadotropin-releasing hormone analogues, Tibolone, ‘Add-back’ therapy",
author = "Wei Liu and Chao Chen and Jun Shi and Xingxing Zang and Zhao, {Ai Min}",
year = "2016",
month = "10",
day = "30",
language = "English (US)",
volume = "9",
pages = "19935--19943",
journal = "International Journal of Clinical and Experimental Medicine",
issn = "1940-5901",
publisher = "e-Century Publishing Corporation",
number = "10",

}

TY - JOUR

T1 - Clinical outcome of various regimens of gonadotropin-releasing hormone analogues after conservative surgery in patients with endometriosis

AU - Liu, Wei

AU - Chen, Chao

AU - Shi, Jun

AU - Zang, Xingxing

AU - Zhao, Ai Min

PY - 2016/10/30

Y1 - 2016/10/30

N2 - Objective: To assess the efficacy of three GnRHa therapies after conservative surgery for ovarian endometriosis by analyzing sex hormones, hypo-estrogenic symptoms, quality of life and bone mineral density. Methods: Thirty-six ovarian endometriosis patients with 20 to 48 years old were divided into three groups after conservative surgery according to their own wills. GnRHa conventional dosage regimen group was intramuscularly injected of triptorelin 3.75 mg every 4 weeks. Tibolone ‘add-back’ therapy group received the same treatment as the conventional group and orally took tibolone tablets 1.25 mg/d from the eighth week. GnRHa extended-interval dosage group received a 4-dose regimen every 6 weeks. The treatment lasted for 24 weeks. The EMs (VAS score), menopausal score, recurrence, menstruation and vaginal bleeding were assessed. The levels in sex hormones, bone metabolism indicators, lumbar spine bone mineral density, CA125 and other parameters were observed. Results: The symptoms including dysmenorrhea, dyspareunia and chronic pelvic pain were relieved in three groups. At 12th and 24th week of GnRHa treatment, the levels of serum sex hormones (FSH, LH and E2) in all groups were decreased compared with the baseline, the modified Kupperman scores in Tibolone ‘add-back’ group and extended-interval group were lower than those of the conventional group. At the end of the 24th week, T scores and CA125 serum in all groups were decreased compared with the baseline. Conclusions: Tibolone ‘add-back’ therapy and GnRHa extended-interval regimen had better effects on improving symptoms of perimenopause than GnRHa conventional regimens. Tibolone ‘add-back’ therapy was more effective in protection of bone density than other treatments.

AB - Objective: To assess the efficacy of three GnRHa therapies after conservative surgery for ovarian endometriosis by analyzing sex hormones, hypo-estrogenic symptoms, quality of life and bone mineral density. Methods: Thirty-six ovarian endometriosis patients with 20 to 48 years old were divided into three groups after conservative surgery according to their own wills. GnRHa conventional dosage regimen group was intramuscularly injected of triptorelin 3.75 mg every 4 weeks. Tibolone ‘add-back’ therapy group received the same treatment as the conventional group and orally took tibolone tablets 1.25 mg/d from the eighth week. GnRHa extended-interval dosage group received a 4-dose regimen every 6 weeks. The treatment lasted for 24 weeks. The EMs (VAS score), menopausal score, recurrence, menstruation and vaginal bleeding were assessed. The levels in sex hormones, bone metabolism indicators, lumbar spine bone mineral density, CA125 and other parameters were observed. Results: The symptoms including dysmenorrhea, dyspareunia and chronic pelvic pain were relieved in three groups. At 12th and 24th week of GnRHa treatment, the levels of serum sex hormones (FSH, LH and E2) in all groups were decreased compared with the baseline, the modified Kupperman scores in Tibolone ‘add-back’ group and extended-interval group were lower than those of the conventional group. At the end of the 24th week, T scores and CA125 serum in all groups were decreased compared with the baseline. Conclusions: Tibolone ‘add-back’ therapy and GnRHa extended-interval regimen had better effects on improving symptoms of perimenopause than GnRHa conventional regimens. Tibolone ‘add-back’ therapy was more effective in protection of bone density than other treatments.

KW - Conservative surgery

KW - Endometriosis

KW - Gonadotropin-releasing hormone analogues

KW - Tibolone

KW - ‘Add-back’ therapy

UR - http://www.scopus.com/inward/record.url?scp=84994372733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994372733&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84994372733

VL - 9

SP - 19935

EP - 19943

JO - International Journal of Clinical and Experimental Medicine

JF - International Journal of Clinical and Experimental Medicine

SN - 1940-5901

IS - 10

M1 - IJCEM0027833

ER -